表紙
市場調查報告書

體外 (In Vitro) ADME實驗服務的全球市場:2019年∼2030年

In Vitro ADME Testing Services Market, 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 778075
出版日期 內容資訊 英文 317 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
體外 (In Vitro) ADME實驗服務的全球市場:2019年∼2030年 In Vitro ADME Testing Services Market, 2019-2030
出版日期: 2019年01月23日內容資訊: 英文 317 Pages
簡介

醫藥品/生物科技部門的研究開發倡議的總支出額,從2008年的1,280億美元,擴大到2018年的1,650億美元。

本報告提供體外 (In Vitro) ADME實驗服務市場相關調查分析,市場形勢,主要企業,法規,市場預測等相關的系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 關於外包

第5章 市場形勢

  • 概要
  • 主要企業的清單

第6章 企業簡介

  • 概要
  • 北美據點的主要企業
    • Albany Molecular Research (AMRI)
    • Charles River Laboratories
    • Pharmaceutical Product Development (PPD)
    • RTI International
  • 歐洲據點的主要企業
    • Eurofins Scientific
    • Evotec
    • Galapagos
    • Tecan Group
  • 亞太地區據點的主要企業
    • GVK Biosciences
    • Pharmaron
    • Sai Life Sciences
    • Shanghai Medicilon
    • Syngene International
    • WuXi AppTec

第7章 基準分析

  • 概要
  • 調查手法
  • 同儕團體
  • 結論

第8章 M&A

  • 概要
  • M&A

第9章 法規相關建議和指南

  • 概要
  • 法規的指南 (國際法規機關)
  • 法規的指南 (地區的法規機關)
  • 法規核准相關資訊

第10章 市場預測

  • 概要
  • 預測手法主要的前提條件
  • 綜合市場
  • 分佈:各地區
  • 分佈:服務的各類型
  • 分佈:化驗的各類型
  • 分佈:各分子類型
  • 分佈:各治療領域
  • 分佈:贊助商的各類型

第11章 結論

第12章 執行考察

  • 概要
  • 490 BioTech
  • JRF Global

第13章 附錄1

第14章 附錄2

目錄
Product Code: RA100125

Example Insights:

Driven by a growing demand for effective therapeutics and an increase in drug discovery efforts across various therapeutic areas, the market is expected to witness sustained growth in future at a healthy CAGR of over 6%.

Overview:

The early stages of drug discovery research, which include the identification of a relevant biological target and a viable lead compound with therapeutic potential, play a crucial role in the overall success of a drug candidate in both preclinical and clinical studies. It is also important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent in R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small fraction of early stage therapeutic candidates are able to make it past preclinical evaluation. According to a study conducted on terminated drug development programs, the high rate of failure of drugs in clinical trials was primarily attributed to problems associated with their pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity. As a result, the industry is currently under tremendous pressure to not only meet the expectations of a growing patient population, but to also identify ways to mitigate the risks associated with discovery programs of novel drug / therapy molecules.

“Earlier, customers from North America demonstrated a preference for service providers within the US to outsource their ADME requirements; however, clients are now more willing to work across borders. Despite growing activity in other upcoming regions, I believe that the major proportion of activity in this field is still restricted to within North America, followed by Asia-Pacific and Europe. ” -- Chief Scientific Officer, a US-based small-sized CRO.

Specifically,ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates. Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services. Over time, such service providers have grown to become an indispensable part of the pharmaceutical / biopharmaceutical market. Moreover, advances in combinatorial chemistry and high throughput screening in the last decade have made it possible to carry out early stage ADME screening for a large number of compounds in a more cost and time efficient manner. In less than a decade, the ADME services industry has witnessed noteworthy consolidation, with many of the smaller players being acquired by more established firms in efforts to augment services portfolios and widen geographical reach. Further, given the growing demand for high quality pharmacological interventions, and the cost and time-related benefits of outsourcing in vitro ADME research, the demand for CROs is projected to grow significantly in the foreseen future.

Synopsis:

The ‘In Vitro ADME Testing Services Market, 2019-2030’ report features a comprehensive study of the current landscape of in vitro ADME testing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders across different global regions. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, featuring a comprehensive list of over 90 CROs that offer in vitro ADME testing services, and analyses based on a number of parameters, such as year of establishment, headquarter location(s), company size, type of additional service(s) offered (in vivo ADME, in silico ADME and toxicology testing), range of assays offered within in vitro ADME service portfolio (blood to plasma ratio, Caco-2 permeability, cytochrome (CYP) enzyme induction / inhibition, metabolic stability, plasma protein binding, reaction phenotyping and others), type of molecule(s) (biologics and small molecules), and type of clientele (pharmaceutical / biotechnology companies and academic / research institutes).
  • A schematic logo landscape of in vitro ADME service providers, highlighting their geographical distribution (on the basis of location of headquarters) and company size (small-sized (1-50 employees), mid-sized (51-200 employees), large (201-1,000 employees), and very large (>1,000 employees)).
  • A discussion on the various outsourcing business models adopted in this domain, along with a list of key considerations that need to be taken into account by industry stakeholders while selecting a CRO partner.
  • Elaborate profiles of popular in vitro ADME testing service providers, featuring a brief overview of the company, its financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.
  • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2005-2018, along with the geographical distribution of this activity. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
  • A detailed discussion on the various regulatory guidelines related to in vitro ADME testing, which have been laid down by major international / regional regulatory bodies (namely European Medicine Agency (EMA), US Food and Drug Administration (USFDA), Ministry of Health, Labor and Welfare (MHLW), International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use, the Organisation for Economic Co-operation and Development (OECD), and World Health Organization (WHO)).

One of the key objectives of the report is to evaluate the current opportunity and the future potential of the in vitro ADME testing services market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In addition, we have segmented the future opportunity across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories). To account for the uncertainties associated with the in vitro ADME testing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions conducted with several stakeholders in this industry. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. More than 90 CROs currently offer in vitro services for testing ADME properties of drug candidates. The market landscape is highly fragmented, featuring a mix of small-sized (less than 50 employees, 42%), mid-sized (51-200 employees, 17%), large (201-1,000 employees, 16%) and very large (more than 1,000 employees, 25%) companies. Examples of some very large players active in this domain, include (in alphabetical order) Charles River Laboratories, Citoxlab Group, Corning Life Sciences, Eurofins Scientific, Piramal Pharma Solutions, QPS, RTI International, Sigma-Aldrich (acquired by Merck), SRI International, Tecan Group and Unilabs Serving Pharma.On the other hand, players that have recently (since 2013) entered the market include (in alphabetical order) APhaD, Aravali Pharma & Lifesciences, Concept Life Sciences, Envigo, IONTOX, Neuro-Sys, Q2 Solutions and Touchstone Biosciences.
  • 2. Majority of the aforementioned CROs (80%) are based in North America and Europe. However, a growing proportion of such players are situated in the Asia-Pacific region. Examples of large companies based in this region include (in alphabetical order, no selection criteria) ChemPartner, GVK Biosciences, JOINN Laboratories, JRF Global, Jubilant Biosys, Medicilon, Pharmaron, Sai Life Sciences, Suven Life Sciences, Syngene International, TCG Lifesciences, Viva Biotech and WuXi AppTec.
  • 3. Of the total number of in vitro ADME service providers, over 85% companies claim to offer assays for drug metabolism testing, which include UGT / CYP enzyme inhibition / induction assays (73), metabolite profiling and screening / identification (60), metabolic stability / metabolic clearance (55), reaction phenotyping (36), metabolite production (21) and transporter interactions (20). Further, over 60 companies claim to have capabilities to conduct absorption and distribution related studies, respectively.
  • 4. Around 55% of the CROs claim to have the necessary expertise to offer services for testing the absorption, distribution, metabolism profiles of drug molecules. Examples of popular companies that claim to offer therequired expertise to evaluate the aforementioned parameters, include (in alphabetical order, no selection criteria) AMRI, CanAm Bioresearch, CEMSA, Galapagos, InrexTest, Novamass, PharmaCadence, Pharmacelsus, Pharmidex Pharmaceutical Services, Shanghai Medicilon, Signature Discovery and Q3 Analytical.
  • 5. Over 35 instances of acquisitions have taken place in this domain over the last decade. Examples of companies that were recently acquired include (in reverse chronological order)SNBL USA's preclinical business by Altasciences (August 2018), Optivia Biotechnology by BioIVT (July 2018), MetaSafe by Admescope (June 2018),Concord Biosciences by Frontage Laboratories (April 2018), MPI Research by Charles River Laboratories(April 2018) and SOLVO Biotechnology by Citoxlab Group (March 2018).
  • 6. Driven by a rising number of candidate drugs that enter the discovery stage across various therapeutic areas, we expect the in vitro ADME testing services market to grow at an annualized rate of nearly ~6% between 2019 and 2030. Based on our estimates, therapies targeting various cancers are expected to be responsible for 46% of the revenues generated within the market by 2030; this is likely to be followed by candidates targeting neurological disorders (13%), immunological disorders (7%) and infectious diseases (5%).
  • 7. North America (primarily the US) and Europe currently hold the larger share (in terms of revenues, over 70%) within the overall in vitro ADME testing services market. This is followed by the Asia-Pacific region and the rest of the world. Within Asia-Pacific, markets in China and Japan are expected to grow at a relatively faster rate (~7%) in the coming decade. We are led to believe that the abovementioned trend is not likely to change significantly in the foreseen future.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the in vitro ADME testing services market and its likely evolution in the short-mid and long term.

Chapter 3 provides an introduction to the overall drug discovery process, with details on the time taken for a drug to traverse through the various stages of drug development and into the market. It includes an overview of ADME testing, featuring a detailed discussion on the significance of evaluating various ADME parameters within the drug discovery and development process. Further, the chapter presents insights on the benefits of carrying out ADME testing at early stages of drug development. It also features details related to various contract services that can be availed by industry stakeholders seeking to outsource ADME testing.

Chapter 4 features a detailed discussion on the various outsourcing related business models that are commonly adopted by the industry stakeholders in relation to ADME testing. The chapter includes a list of factors that drive sponsors to outsource their ADME testing operations. It also highlights several key parameters that sponsors need to take into consideration while choosing a CRO partner. The chapter features an elaborate discussion on benefits of outsourcing ADME services, along with the affiliated risks and challenges.

Chapter 5 provides a comprehensive view on the global landscape of in vitro ADME testing service providers. It includes information related to over 90 CROs that claim to offer in vitro ADME services, featuring in-depth analyses of the players based on their year of establishment, headquarter location(s), company size, type of additional service(s) offered, range of assays offered within in vitro ADME service portfolio, type of molecule(s), and type of clientele. The chapter also includes a list of 70 players offering in silico ADME services. In addition, it also features a logo landscape of the players that claim to offer in vitro ADME services, distributed on the basis of the location of their respective headquarters and company size.

Chapter 6 features detailed profiles of key CROs that claim to offer in vitro ADME testing services, across different geographies. Each company profile includes a brief overview of the company, financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.

Chapter 7presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to in vitro ADME testing. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 8 features a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2005 to 2018. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.

Chapter 9 features information on the regulatory guidelines that have been laid down by key regulatory bodies / organizations, specific to ADME testing in the pharmaceutical industry. These are EMA, ICH, MHLW, OECD, USFDA and WHO.

Chapter 10 features a comprehensive market forecast, highlighting the future potential of in vitro ADME testing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories).

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the biopharmaceutical industry.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Dan Close (Chief Scientific Officer, 490 BioTech), and Sridhar Iyer (Director and Global Head, Business Development, JRF Global) and Sarang Gorte (Assistant Manager, Business Development, JRF Global).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. The Drug Discovery and Development Process
  • 3.3. Introduction to Absorption, Distribution, Metabolism and Excretion (ADME) Testing
    • 3.3.1. Absorption
    • 3.3.2. Distribution
    • 3.3.3. Metabolism
    • 3.3.4. Excretion
  • 3.4. Importance of ADME Studies in Early Stage Research
  • 3.5. Types of ADME Studies in Discovery and Preclinical Development
  • 3.6. Types of Assays Used in ADME Testing
  • 3.7. Types of ADME Testing Studies
    • 3.7.1. In Vitro ADME Testing Studies
    • 3.7.2. In Silico ADME Testing Studies
    • 3.7.3. In Vivo ADME Testing Studies
  • 3.8. Key Drivers for ADME Testing Studies
  • 3.9. Concluding Remarks

4. GUIDE TO OUTSOURCING

  • 4.1. Chapter Overview
  • 4.2. Outsourcing ADME Testing Services
  • 4.3. Guiding Models for Outsourcing
    • 4.3.1. Transactional Outsourcing Model
    • 4.3.2. Performance-based Outsourcing Model
    • 4.3.3. Outcomes-based Outsourcing Model
    • 4.3.4. Phase-dependent Outsourcing Model
  • 4.4. Selecting a Contract Research Organization (CRO) Partner
    • 4.4.1. Key Considerations
  • 4.5. Role of CROs in Drug Development
    • 4.5.1. Discovery and Preclinical Research
    • 4.5.2. Early Clinical Research
    • 4.5.3. Late Stage Clinical Research
  • 4.6. Benefits of Outsourcing ADME Testing Services
  • 4.7. Risks and Challenges Associated with Outsourcing ADME Testing Services
  • 4.8. Concluding Remarks

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. In Vitro ADME Testing Services: List of Industry Players
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Geographical Location
    • 5.2.3. Analysis by Company Size
    • 5.2.4. Analysis by Type of Service Offering
    • 5.2.5. Analysis by Type of In Vitro ADME Assays
    • 5.2.6. Analysis by Type of Molecule
    • 5.2.7. Analysis by Type of Clientele
    • 5.2.8. Logo Landscape: Distribution by Company Size and Location of Headquarters
  • 5.3 In Silico ADME Testing Services: List of Industry Players

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Key Players based in North America
    • 6.2.1. Albany Molecular Research (AMRI)
      • 6.2.1.1. Company Snapshot
      • 6.2.1.2. Financial Information
      • 6.2.1.3. ADME Testing Specific Service Portfolio
      • 6.2.1.4. Recent Developments and Future Outlook
    • 6.2.2. Charles River Laboratories
      • 6.2.2.1. Company Snapshot
      • 6.2.2.2. Financial Information
      • 6.2.2.3. ADME Testing Specific Service Portfolio
      • 6.2.2.4. Recent Developments and Future Outlook
    • 6.2.3. Pharmaceutical Product Development (PPD)
      • 6.2.3.1. Company Snapshot
      • 6.2.3.2. ADME Testing Specific Service Portfolio
      • 6.2.3.3. Recent Developments and Future Outlook
    • 6.2.4. RTI International
      • 6.2.4.1. Company Snapshot
      • 6.2.4.2. Financial Information
      • 6.2.4.3. ADME Testing Specific Service Portfolio
      • 6.2.4.4. Recent Developments and Future Outlook
  • 6.3. Key Players based in Europe
    • 6.3.1. Eurofins Scientific
      • 6.3.1.1. Company Snapshot
      • 6.3.1.2. Financial Information
      • 6.3.1.3. ADME Testing Specific Service Portfolio
      • 6.3.1.4. Recent Developments and Future Outlook
    • 6.3.2. Evotec
      • 6.3.2.1. Company Snapshot
      • 6.3.2.2. Financial Information
      • 6.3.2.3. ADME Testing Specific Service Portfolio
      • 6.3.2.4. Recent Developments and Future Outlook
    • 6.3.3. Galapagos
      • 6.3.3.1. Company Snapshot
      • 6.3.3.2. Financial Information
      • 6.3.3.3. ADME Testing Specific Service Portfolio
      • 6.3.3.4. Recent Developments and Future Outlook
    • 6.3.4. Tecan Group
      • 6.3.4.1. Company Snapshot
      • 6.3.4.2. Financial Information
      • 6.3.4.3. ADME Testing Specific Service Portfolio
      • 6.3.4.4. Recent Developments and Future Outlook
  • 6.4. Key Players based in Asia-Pacific
    • 6.4.1. GVK Biosciences
      • 6.4.1.1. Company Snapshot
      • 6.4.1.2. ADME Testing Specific Service Portfolio
      • 6.4.1.3. Recent Developments and Future Outlook
    • 6.4.2. Pharmaron
      • 6.4.2.1. Company Snapshot
      • 6.4.2.2. ADME Testing Specific Service Portfolio
      • 6.4.2.3. Recent Developments and Future Outlook
    • 6.4.3. Sai Life Sciences
      • 6.4.3.1. Company Snapshot
      • 6.4.3.2. ADME Testing Specific Service Portfolio
      • 6.4.3.3. Recent Developments and Future Outlook
    • 6.4.4. Shanghai Medicilon
      • 6.4.4.1. Company Snapshot
      • 6.4.4.2. ADME Testing Specific Service Portfolio
      • 6.4.4.3. Recent Developments and Future Outlook
    • 6.4.5. Syngene International
      • 6.4.5.1. Company Snapshot
      • 6.4.5.2. Financial Information
      • 6.4.5.3. ADME Testing Specific Service Portfolio
      • 6.4.5.4. Recent Developments and Future Outlook
    • 6.4.6. WuXi AppTec
      • 6.4.6.1. Company Snapshot
      • 6.4.6.2. Financial Information
      • 6.4.6.3. ADME Testing Specific Service Portfolio
      • 6.4.6.4. Recent Developments and Future Outlook

7. BENCHMARK ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Benchmark Analysis: Methodology
  • 7.3. Benchmark Analysis: Peer Groups
    • 7.3.1. Peer Group I
    • 7.3.2. Peer Group II
    • 7.3.3. Peer Group III
    • 7.3.4. Peer Group IV
    • 7.3.5. Peer Group V
    • 7.3.6. Peer Group VI
    • 7.3.7. Peer Group VII
    • 7.3.8. Peer Group VIII
  • 7.4. Concluding Remarks

8. MERGERS AND ACQUISITIONS

  • 8.1. Chapter Overview
  • 8.2. In Vitro ADME Testing Services: Mergers and Acquisitions
    • 8.2.1. Cumulative Year-wise Trend
    • 8.2.2. Geographical Activity
    • 8.2.3. Ownership Change Matrix
    • 8.2.4. Most Active Players: Analysis by Number of Acquisitions
    • 8.2.5. Key Value Drivers
    • 8.2.6. Key Acquisitions: Deal Multiples

9. REGULATORY RECOMMENDATIONS AND GUIDELINES

  • 9.1. Chapter Overview
  • 9.2. Regulatory Guidelines Issued by International Regulatory Agencies
    • 9.2.1. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
    • 9.2.2. World Health Organization (WHO)
    • 9.2.3. Organisation for Economic Co-operation and Development (OECD)
  • 9.3. Regulatory Guidelines Issued by Regional Regulatory Agencies
    • 9.3.1. United States Food and Drug Administration (USFDA), US
    • 9.3.2. European Medicine Agency (EMA), Europe
    • 9.3.3. Ministry of Health, Labour and Welfare (MHLW), Japan
  • 9.4. In Vitro ADME Testing Service Providers: Information on Regulatory Approval

10. MARKET FORECAST

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Overall In Vitro ADME Testing Services Market, 2019-2030
  • 10.4. In Vitro ADME Testing Services Market: Distribution by Regions, 2019-2030
    • 10.4.1. In Vitro ADME Testing Services Market in North America, 2019-2030
      • 10.4.1.1. In Vitro ADME Testing Services Market in the US, 2019-2030
      • 10.4.1.2. In Vitro ADME Testing Services Market in Canada, 2019-2030
    • 10.4.2. In Vitro ADME Testing Services Market in Europe, 2019-2030
      • 10.4.2.1. In Vitro ADME Testing Services Market in Germany, 2019-2030
      • 10.4.2.2. In Vitro ADME Testing Services Market in France, 2019-2030
      • 10.4.2.3. In Vitro ADME Testing Services Market in the UK, 2019-2030
      • 10.4.2.4. In Vitro ADME Testing Services Market in Italy, 2019-2030
      • 10.4.2.5. In Vitro ADME Testing Services Market in Spain, 2019-2030
      • 10.4.2.6. In Vitro ADME Testing Services Market in Rest of Europe, 2019-2030
    • 10.4.3. In Vitro ADME Testing Services Market in Asia-Pacific and Rest of the World, 2019-2030
      • 10.4.3.1. In Vitro ADME Testing Services Market in Japan, 2019-2030
      • 10.4.3.2. In Vitro ADME Testing Services Market in China, 2018-2028
      • 10.4.3.3. In Vitro ADME Testing Services Market in India, 2019-2030
      • 10.4.3.4. In Vitro ADME Testing Services Market in Rest of the World, 2019-2030
  • 10.5. In Vitro ADME Testing Services Market: Distribution by Type of Services, 2019-2030
    • 10.5.1. In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030
    • 10.5.2. In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030
    • 10.5.3. In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030
    • 10.5.4. In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030
  • 10.6. In Vitro ADME Testing Services Market: Distribution by Type of Assays, 2019-2030
    • 10.6.1. In Vitro ADME Testing Services Market for Caco-2 Permeability Assay, 2019-2030
    • 10.6.2. In Vitro ADME Testing Services Market for Protein Binding Assay, 2019-2030
    • 10.6.3. In Vitro ADME Testing Services Market for Metabolic Stability / Clearance Assay, 2019-2030
    • 10.6.4. In Vitro ADME Testing Services Market for Enzyme Induction Assay, 2019-2030
    • 10.6.5. In Vitro ADME Testing Services Market for Enzyme Inhibition Assay, 2019-2030
    • 10.6.6. In Vitro ADME Testing Services Market for Other Assays, 2019-2030
  • 10.7. In Vitro ADME Testing Services Market: Distribution by Type of Molecules, 2019-2030
    • 10.7.1. In Vitro ADME Testing Services Market for Small Molecules, 2019-2030
    • 10.7.2. In Vitro ADME Testing Services Market for Biologics, 2019-2030
  • 10.8. In Vitro ADME Testing Services Market: Distribution by Therapeutic Areas, 2019-2030
    • 10.8.1. In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030
    • 10.8.2. In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030
    • 10.8.3. In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030
    • 10.8.4. In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030
    • 10.8.5. In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030
    • 10.8.6. In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030
    • 10.8.7. In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030
    • 10.8.8. In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030
    • 10.8.9. In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030
    • 10.8.10. In Vitro ADME Testing Services Market for Cancers, 2019-2030
    • 10.8.11. In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030
    • 10.8.12. In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030
    • 10.8.13. In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030
    • 10.8.14. In Vitro ADME Testing Services Market for Other Disorders, 2019-2030
    • 10.8.15. In Vitro ADME Testing Services Market: Market Attractiveness Analysis by Therapeutic Areas, 2019-2030
  • 10.9. In Vitro ADME Testing Services Market: Distribution by Type of Sponsors, 2019-2030
    • 10.9.1. In Vitro ADME Testing Services Market for Industry Players, 2019-2030
    • 10.9.2. In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030

11. CONCLUSION

  • 11.1. In Vitro ADME Studies Conducted During the Early Stages of Drug Development has Demonstrated the Potential to Improve the Probability of Success in Clinical Trials
  • 11.2. Several CROs Offer Services for In Vitro ADME Testing; Most such Companies are based in North America and Europe
  • 11.3. The Market is Dominated by Players having Vast In Vitro ADME Testing Portfolios; Drug Metabolism-related Assays Represent a Major Fraction of Services
  • 11.4. Stakeholders are Actively Expanding their Existing Capabilities to Cater to the Increasing Demand; this is Evident in Number of Acquisitions Reported over the Past Decade
  • 11.5. Owing to the Benefits of Outsourcing, the In Vitro ADME testing Services Market is Expected to Grow at a Healthy Pace in the Foreseen Future

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. 490 BioTech
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Dan Close, Chief Scientific Officer
  • 12.3. JRF Global
    • 12.3.1. Company Snapshot
    • 12.3.2. Interview Transcript: Sridhar Iyer, Director and Global Head, Business Development and Sarang Gorte, Assistant Manager, Business Development

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Drug Discovery and Development Timeline
  • Figure 3.2: Pharmacokinetics Pathway of a Drug in Human Body
  • Figure 3.3: Comparison of Oral and Intravascular Drug Administration: Role of Hepatic Portal System
  • Figure 3.4: Reasons for Attrition in Drug Development
  • Figure 3.5: ADME Studies in Discovery and Preclinical Development
  • Figure 3.6: Drivers for In Vitro ADME Testing Studies
  • Figure 4.1: Guiding Models for Outsourcing
  • Figure 4.2: Key Characteristics of Transactional Outsourcing Model
  • Figure 4.3: Key Characteristics of Performance-based Outsourcing Model
  • Figure 4.4: Key Steps Leading to Outcomes-based Outsourcing Model
  • Figure 4.5: Factors Influencing Outsourcing Decisions
  • Figure 4.6: Key Considerations to Select a CRO Partner
  • Figure 4.7: Role of a CRO in Different Phases of Drug Development
  • Figure 4.8: End-to-End Integrated Services in Discovery and Preclinical Research
  • Figure 4.9: Benefits of Outsourcing ADME Testing Services
  • Figure 4.10: Challenges Related to Outsourcing ADME Testing Services
  • Figure 5.1: In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
  • Figure 5.2: In Vitro ADME Testing Service Providers: Distribution by Geographical Location
  • Figure 5.3: In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
  • Figure 5.4: In Vitro ADME Testing Service Providers: Distribution by Company Size
  • Figure 5.5: In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
  • Figure 5.6: In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
  • Figure 5.7: In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
  • Figure 5.8: In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
  • Figure 5.9: In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
  • Figure 5.10: In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
  • Figure 5.11: In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
  • Figure 5.12: In Vitro ADME Testing Service Providers Logo Landscape: Distribution by Company Size and Location
  • Figure 6.1: AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
  • Figure 6.2: AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
  • Figure 6.3: AMRI: In Vitro ADME Testing Service Portfolio
  • Figure 6.4: Charles River Laboratories: Business Segments
  • Figure 6.5: Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
  • Figure 6.6: Charles River Laboratories: In Vitro ADME Testing Service Portfolio
  • Figure 6.7: BioDuro: In Vitro ADME Assays Offered
  • Figure 6.8: RTI International: Annual Revenues, 2013-2017 (USD Million)
  • Figure 6.9: RTI International: In Vitro ADME Testing Service Portfolio
  • Figure 6.10: Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
  • Figure 6.11: Eurofins Scientific: In Vitro ADME Testing Service Portfolio
  • Figure 6.12: Evotec: Annual Revenues, 2013-Q1 2018 (EUR Million)
  • Figure 6.13: Evotec: Revenues by Business Segments, 2017 (EUR Million)
  • Figure 6.14: Evotec: Drug Discovery Services
  • Figure 6.15: Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
  • Figure 6.16: Galapagos: In Vitro ADME Testing Service Portfolio
  • Figure 6.17: Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
  • Figure 6.18: Tecan Group: In Vitro ADME Testing Service Portfolio
  • Figure 6.19: GVK Biosciences: Business Segments
  • Figure 6.20: GVK Biosciences: In Vitro ADME Testing Service Portfolio
  • Figure 6.21: Pharmaron: In Vitro ADME Service Portfolio
  • Figure 6.22: Sai Life Sciences: In Vitro ADME Testing Service Portfolio
  • Figure 6.23: Shanghai Medicilon: In Vitro ADME Testing Service Portfolio
  • Figure 6.24: Syngene International: Annual Revenues, 2012-H1 2018 (INR Million)
  • Figure 6.25: Syngene International: In Vitro ADME Testing Service Portfolio
  • Figure 6.26: WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
  • Figure 6.27: WuXi AppTec: In Vitro ADME Testing Service Portfolio
  • Figure 7.1: Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
  • Figure 7.2: Benchmark Analysis: Peer Group I
  • Figure 7.3: Benchmark Analysis: Peer Group II
  • Figure 7.4: Benchmark Analysis: Peer Group III
  • Figure 7.5: Benchmark Analysis: Peer Group IV
  • Figure 7.6: Benchmark Analysis: Peer Group V
  • Figure 7.7: Benchmark Analysis: Peer Group VI
  • Figure 7.8: Benchmark Analysis: Peer Group VII
  • Figure 7.9: Benchmark Analysis: Peer Group VIII
  • Figure 7.10: Benchmark Analysis: Comparison Across Peer Groups
  • Figure 8.1: Acquisitions: Year-Wise Cumulative Trend (2005-2018)
  • Figure 8.2: Acquisitions: Regional Distribution
  • Figure 8.3: Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Figure 8.4: Acquisitions: Ownership Change Matrix
  • Figure 8.5: Acquisitions: Most Active Acquirers
  • Figure 8.6: Acquisitions: Key Value Drivers
  • Figure 8.7: Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
  • Figure 9.1: Regulatory Guidelines for Non-Clinical Studies
  • Figure 9.2: ICH: Regulatory and Industry Participants
  • Figure 9.3: ICH: Guidance Documents for Non-Clinical Studies
  • Figure 9.4: USFDA: GLP Guidelines for Non-Clinical Studies
  • Figure 9.5: Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
  • Figure 10.1: Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
  • Figure 10.2: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
  • Figure 10.3: In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
  • Figure 10.4: In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Billion)
  • Figure 10.5: In Vitro ADME Testing Services Market, 2019-2030: US, Base Scenario (USD Million)
  • Figure 10.6: In Vitro ADME Testing Services Market, 2019-2030: Canada, Base Scenario (USD Million)
  • Figure 10.7: In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Billion)
  • Figure 10.8: In Vitro ADME Testing Services Market, 2019-2030: Germany, Base Scenario (USD Million)
  • Figure 10.9: In Vitro ADME Testing Services Market, 2019-2030: France, Base Scenario (USD Million)
  • Figure 10.10: In Vitro ADME Testing Services Market, 2019-2030: UK, Base Scenario (USD Million)
  • Figure 10.11: In Vitro ADME Testing Services Market, 2019-2030: Italy, Base Scenario (USD Million)
  • Figure 10.12: In Vitro ADME Testing Services Market, 2019-2030: Spain, Base Scenario (USD Million)
  • Figure 10.13: In Vitro ADME Testing Services Market, 2019-2030: Rest of Europe, Base Scenario (USD Million)
  • Figure 10.14: In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Billion)
  • Figure 10.15: In Vitro ADME Testing Services Market, 2019-2030: Japan, Base Scenario (USD Million)
  • Figure 10.16: In Vitro ADME Testing Services Market, 2019-2030: China, Base Scenario (USD Million)
  • Figure 10.17: In Vitro ADME Testing Services Market, 2019-2030: India, Base Scenario (USD Million)
  • Figure 10.18: In Vitro ADME Testing Services Market, 2019-2030: Rest of the World, Base Scenario (USD Million)
  • Figure 10.19: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
  • Figure 10.20: In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
  • Figure 10.21: In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030: Base Scenario (USD Million)
  • Figure 10.22: In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030: Base Scenario (USD Million)
  • Figure 10.23: In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030: Base Scenario (USD Million)
  • Figure 10.24: In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030: Base Scenario (USD Million)
  • Figure 10.25: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
  • Figure 10.26: In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
  • Figure 10.27: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Caco-2 Permeability Assay, Base Scenario (USD Million)
  • Figure 10.28: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Protein Binding Assay, Base Scenario (USD Million)
  • Figure 10.29: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Metabolic Stability / Clearance Assay, Base Scenario (USD Million)
  • Figure 10.30: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Induction Assay, Base Scenario (USD Million)
  • Figure 10.31: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Inhibition Assay, Base Scenario (USD Million)
  • Figure 10.32: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Other Assays, Base Scenario (USD Million)
  • Figure 10.33: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
  • Figure 10.34: In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
  • Figure 10.35: In Vitro ADME Testing Services Market for Small Molecules, 2019-2030: Base Scenario (USD Billion)
  • Figure 10.36: In Vitro ADME Testing Services Market for Biologics, 2019-2030: Base Scenario (USD Billion)
  • Figure 10.37: In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.38: In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.39: In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.40: In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.41: In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030: Base Scenario (USD Million)
  • Figure 10.42: In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.43: In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.44: In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.45: In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.46: In Vitro ADME Testing Services Market for Cancers, 2019-2030: Base Scenario (USD Million)
  • Figure 10.47: In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.48: In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.49: In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.50: In Vitro ADME Testing Services Market for Other Disorders, 2019-2030: Base Scenario (USD Million)
  • Figure 10.51: In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness by Therapeutic Areas, Base Scenario (USD Million)
  • Figure 10.52: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
  • Figure 10.53: In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030
  • Figure 10.54: In Vitro ADME Testing Services Market for Industry Players, 2019-2030: Base Scenario (USD Billion)
  • Figure 10.55: In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030: Base Scenario (USD Billion)
  • Figure 11.1: Overall In Vitro ADME Testing Services Market, Conservative, Base and Optimistic Scenarios, 2019, 2024 and 2030 (USD Billion)

List of Tables:

  • Table 3.1: List of Assays Performed During ADME Studies
  • Table 5.1: In Vitro ADME Testing Services: List of Industry Players
  • Table 5.2: In Vitro ADME Testing Service Providers: Information on Type of In Vitro ADME Testing Services
  • Table 5.3: In Vitro ADME Testing Service Providers: Information on Type of Molecule
  • Table 5.4: In Vitro ADME Testing Service Providers: Information on Type of Clientele
  • Table 5.5: In Silico ADME Testing Services: List of Industry Players
  • Table 6.1: In Vitro ADME Testing Services: List of Companies Profiled
  • Table 6.2: AMRI: Key Highlights
  • Table 6.3: AMRI: Recent / Past Trends and Future Outlook
  • Table 6.4: Charles River Laboratories: Key Highlights
  • Table 6.5: Charles River Laboratories: Recent / Past Trends and Future Outlook
  • Table 6.6: BioDuro: Key Highlights
  • Table 6.7: BioDuro: Recent / Past Trends and Future Outlook
  • Table 6.8: RTI International: Key Highlights
  • Table 6.9: RTI International: Recent / Past Trends and Future Outlook
  • Table 6.10: Eurofins Scientific: Key Highlights
  • Table 6.11: Eurofins Scientific: Recent / Past Trends and Future Outlook
  • Table 6.12: Evotec: Key Highlights
  • Table 6.13: Evotec: In Vitro ADME Assays Offered
  • Table 6.14: Evotec: Recent / Past Trends and Future Outlook
  • Table 6.15: Galapagos: Key Highlights
  • Table 6.16: Galapagos: Recent / Past Trends and Future Outlook
  • Table 6.17: Tecan Group: Key Highlights
  • Table 6.18: Tecan Group: Recent / Past Trends and Future Outlook
  • Table 6.19: GVK Biosciences: Key Highlights
  • Table 6.20: GVK Biosciences: Recent / Past Trends and Future Outlook
  • Table 6.21: Pharmaron: Key Highlights
  • Table 6.22: Pharmaron: Recent / Past Trends and Future Outlook
  • Table 6.23: Sai Life Sciences: Key Highlights
  • Table 6.24: Sai Life Sciences: Recent / Past Trends and Future Outlook
  • Table 6.25: Shanghai Medicilon: Key Highlights
  • Table 6.26: Shanghai Medicilon: Recent / Past Trends and Future Outlook
  • Table 6.27: Syngene International: Key Highlights
  • Table 6.28: Syngene International: Recent / Past Trends and Future Outlook
  • Table 6.29: WuXi AppTec: Key Highlights
  • Table 6.30: WuXi AppTec: Recent / Past Trends and Future Outlook
  • Table 7.1: Benchmark Analysis: Peer Groups
  • Table 8.1: In Vitro ADME Testing Services: Mergers and Acquisitions
  • Table 8.2: In Vitro ADME Testing Services: Information on Key Value Drivers of Acquisitions
  • Table 8.3: Key Acquisitions: Deal Multiples
  • Table 9.1: USFDA: Guidance Documents for Non-Clinical Studies
  • Table 9.2: EMA: Guidance Documents for Non-Clinical Studies
  • Table 9.3: MHLW: Guidance Documents for Non-Clinical Studies
  • Table 9.4: In Vitro ADME Testing Service Providers: Information on Regulatory Approval
  • Table 12.1: 490 BioTech: Key Highlights
  • Table 12.2: JRF Global: Key Highlights
  • Table 13.1: Reasons for Attrition in Drug Development
  • Table 13.2: In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
  • Table 13.3: In Vitro ADME Testing Service Providers: Distribution by Geographical Location
  • Table 13.4: In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
  • Table 13.5: In Vitro ADME Testing Service Providers: Distribution by Company Size
  • Table 13.6: In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
  • Table 13.7: In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
  • Table 13.8: In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
  • Table 13.9: In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
  • Table 13.10: In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
  • Table 13.11: In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
  • Table 13.12: In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
  • Table 13.13: AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
  • Table 13.14: AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
  • Table 13.15: Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
  • Table 13.16: RTI International: Annual Revenues, 2013-2017 (USD Million)
  • Table 13.17: Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
  • Table 13.18: Evotec: Annual Revenues, 2013-Q1 2018 (EUR Million)
  • Table 13.19: Evotec: Revenues by Business Segments, 2017 (EUR Million)
  • Table 13.20: Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
  • Table 13.21: Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
  • Table 13.22: Syngene International: Annual Revenues, 2012-H1 2018 (INR Million)
  • Table 13.23: WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
  • Table 13.24: Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
  • Table 13.25: Benchmark Analysis: Peer Group I
  • Table 13.26: Benchmark Analysis: Peer Group II
  • Table 13.27: Benchmark Analysis: Peer Group III
  • Table 13.28: Benchmark Analysis: Peer Group IV
  • Table 13.29: Benchmark Analysis: Peer Group V
  • Table 13.30: Benchmark Analysis: Peer Group VI
  • Table 13.31: Benchmark Analysis: Peer Group VII
  • Table 13.32: Benchmark Analysis: Peer Group VIII
  • Table 13.33: Acquisitions: Year-Wise Cumulative Trend (2005-2018)
  • Table 13.34: Acquisitions: Regional Distribution
  • Table 13.35: Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Table 13.36: Acquisitions: Ownership Change Matrix
  • Table 13.37: Acquisitions: Most Active Acquirers
  • Table 13.38: Acquisitions: Key Value Drivers
  • Table 13.39: Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
  • Table 13.40: Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
  • Table 13.41: Overall In Vitro ADME Testing Services Market, 2019-2030: Conservative Scenario (USD Billion)
  • Table 13.42: Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
  • Table 13.43: Overall In Vitro ADME Testing Services Market, 2019-2030: Optimistic Scenario (USD Billion)
  • Table 13.44: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Conservative Scenario (USD Billion)
  • Table 13.45: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
  • Table 13.46: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Optimistic Scenario (USD Billion)
  • Table 13.47: In Vitro ADME Testing Services Market, 2019-2030: North America, Conservative Scenario (USD Million)
  • Table 13.48: In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Million)
  • Table 13.49: In Vitro ADME Testing Services Market, 2019-2030: North America, Optimistic Scenario (USD Million)
  • Table 13.50: In Vitro ADME Testing Services Market, 2019-2030: Europe, Conservative Scenario (USD Million)
  • Table 13.51: In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Million)
  • Table 13.52: In Vitro ADME Testing Services Market, 2019-2030: Europe, Optimistic Scenario (USD Million)
  • Table 13.53: In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Conservative Scenario (USD Million)
  • Table 13.54: In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
  • Table 13.55: In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Optimistic Scenario (USD Million)
  • Table 13.56: In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
  • Table 13.57: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Conservative Scenario (USD Million)
  • Table 13.58: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
  • Table 13.59: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Optimistic Scenario (USD Million)
  • Table 13.60: In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
  • Table 13.61: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Conservative Scenario (USD Million)
  • Table 13.62: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
  • Table 13.63: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Optimistic Scenario (USD Million)
  • Table 13.64: In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
  • Table 13.65: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Conservative Scenario (USD Billion)
  • Table 13.66: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
  • Table 13.67: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Optimistic Scenario (USD Billion)
  • Table 13.68: In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
  • Table 13.69: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Conservative Scenario (USD Million)
  • Table 13.70: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Base Scenario (USD Million)
  • Table 13.71: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Optimistic Scenario (USD Million)
  • Table 13.72: In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness Analysis by Therapeutic Areas (USD Million)
  • Table 13.73: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Conservative Scenario (USD Billion)
  • Table 13.74: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
  • Table 13.75: In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Optimistic Scenario (USD Billion)
  • Table 13.76: In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030

Company Listed:

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 490 BioTech
  • 2. Aaranya Biosciences
  • 3. AbbVie
  • 4. Accelera
  • 5. Advanced Chemistry Development Labs
  • 6. Admescope
  • 7. ADMETRx
  • 8. Advancell Advanced In Vitro Cell Technologies
  • 9. Agilux Laboratories
  • 10. Allesh Biosciences Labs
  • 11. Altasciences
  • 12. AMRI
  • 13. Analiza
  • 14. Antengene
  • 15. APEIRON Biologics
  • 16. APhaD
  • 17. Apredica
  • 18. Aptuit
  • 19. Aragen Bioscience
  • 20. Aravali Pharma & Lifesciences
  • 21. Asahi Kasei Pharma
  • 22. Astellas Analytical Science Laboratories
  • 23. AstraZeneca
  • 24. Aurigon
  • 25. Aurora Fine Chemicals
  • 26. Avistron Chemistry Services
  • 27. Baxter
  • 28. Biaffin
  • 29. Bienta
  • 30. BioAscent
  • 31. Biocon
  • 32. BioDuro
  • 33. BioIVT
  • 34. Bionomics
  • 35. Biotech Investment Group
  • 36. Biotranex
  • 37. BLIRT
  • 38. BloodCenter of Wisconsin
  • 39. Blue Stream Laboratories
  • 40. BOC Sciences
  • 41. Brains On-Line
  • 42. BRI Biopharmaceutical Research
  • 43. Brunswick Labs
  • 44. Caliper Life Sciences
  • 45. Calvert Laboratories
  • 46. CanAm Bioresearch
  • 47. Cangenix
  • 48. CapEval Pharma
  • 49. Carna Biosciences
  • 50. Carrick Therapeutics
  • 51. CeeTox
  • 52. Celgene
  • 53. Cellumen
  • 54. Celsis In Vitro Technologies
  • 55. Celsis International
  • 56. CEMSA - Center for Applied Mass Spectrometry
  • 57. Charles River Laboratories
  • 58. ChemBio Discovery Solutions
  • 59. ChemDiv
  • 60. ChemModeling
  • 61. ChemoGenics BioPharma
  • 62. Chemotargets
  • 63. ChemPartner
  • 64. Citoxlab Group
  • 65. Clinical Research Laboratories
  • 66. Cloud Pharmaceuticals
  • 67. Colorado Computational
  • 68. Comparative Biosciences
  • 69. CompChem Solutions
  • 70. Concept Life Sciences
  • 71. Concord Biosciences
  • 72. Corning Life Sciences
  • 73. Covance
  • 74. CR Medicon
  • 75. Creative Animodel
  • 76. Creative Biolabs
  • 77. Creative Biostructure
  • 78. Crelux
  • 79. Crucell
  • 80. Cyclica
  • 81. Cyprotex
  • 82. Dermscan
  • 83. DiaSorin
  • 84. Discover Drugs
  • 85. Distributed Bio
  • 86. Domainex
  • 87. Drik
  • 88. eADMET
  • 89. Eagle Pharmaceuticals
  • 90. ECOSUR
  • 91. EMD Millipore
  • 92. Enamine
  • 93. Entelos
  • 94. Envigo
  • 95. EnvironeX Group
  • 96. Eurofins Scientific
  • 97. Eurofins Cerep
  • 98. European Federation of Pharmaceutical Industries and Associations
  • 99. Eurosafe
  • 100. Evolvus
  • 101. Evotec
  • 102. Excelra Knowledge Solutions
  • 103. Exscientia
  • 104. Fidelta
  • 105. Formex
  • 106. Frontage Laboratories
  • 107. Gadea Pharmaceutical Group
  • 108. Galapagos
  • 109. Genentech
  • 110. GenPharm Tox Biotech
  • 111. Gfree Bio
  • 112. Gilead Sciences
  • 113. Greenpharma
  • 114. GSK
  • 115. GTCR
  • 116. GVK Biosciences
  • 117. HarkerBIO
  • 118. HD Biosciences
  • 119. Health Economics Research Centre
  • 120. Icagen
  • 121. IDSC
  • 122. ImaBiotech
  • 123. In Vitro ADMET Laboratories
  • 124. Innovative Informatica Technologies
  • 125. Inpharmatica
  • 126. InrexTest
  • 127. INSERM
  • 128. International Resources Group
  • 129. INVITEK
  • 130. IONTOX
  • 131. IOTA Pharmaceuticals
  • 132. Japan Pharmaceutical Manufacturers Association
  • 133. Janssen Therapeutics
  • 134. JOINN Laboratories
  • 135. JPT Peptide Technologies
  • 136. JRF GLOBAL
  • 137. Jubilant Biosys
  • 138. Kirklees Biosciences
  • 139. KWS BioTest
  • 140. LabCorp
  • 141. Labo Van Poucke
  • 142. Laxai Avanti Life Sciences
  • 143. LegoChem Biosciences
  • 144. Longthera Pharmaceuticals
  • 145. Mascot Industries
  • 146. MasiMax Resources
  • 147. Mayo Clinic
  • 148. Medisyn Technologies
  • 149. Merck
  • 150. MetaSafe
  • 151. Metrion Biosciences
  • 152. MicroConstants
  • 153. Mind the Byte
  • 154. Molcode
  • 155. Molsoft
  • 156. MorphoSys
  • 157. MPI Research
  • 158. MTTlab
  • 159. Nanolab Technologies
  • 160. National Institute of Allergy and Infectious Disease
  • 161. National Institutes of Health
  • 162. Neuro-Sys
  • 163. NMDL-LCPL
  • 164. Notox
  • 165. NovaData Solutions
  • 166. Novamass
  • 167. NovaMechanics
  • 168. Novartis
  • 169. Novo Informatics
  • 170. NuChem Therapeutics
  • 171. Nuevolution
  • 172. NuGEN Technologies
  • 173. Numerate
  • 174. Oncodesign
  • 175. Optivia Biotechnology
  • 176. Oroxcell
  • 177. Oxford Bioscience Partners
  • 178. Panlabs Biologics
  • 179. PathoQuest
  • 180. PerkinElmer
  • 181. Petra Pharma
  • 182. Pfizer
  • 183. PharmaCadence
  • 184. Pharmacelsus
  • 185. Pharmaceuticals and Medical Devices Agency
  • 186. Pharmaceutical Product Development
  • 187. Pharmaron
  • 188. Pharmidex Pharmaceutical Services
  • 189. PharmOptima
  • 190. PHAST
  • 191. Piramal Pharma Solutions
  • 192. Porton Pharma Solutions
  • 193. Preclinical GPS
  • 194. Prestwick Chemical
  • 195. Prime European Therapeuticals
  • 196. Princeton BioMolecular Research
  • 197. Profacgen
  • 198. ProSciens
  • 199. Prosilico
  • 200. ProtoQSAR
  • 201. ProXyChem
  • 202. Q2 Solutions
  • 203. Q3 Analytical
  • 204. Qualyst Transporter Solutions
  • 205. Quantum Hi-Tech
  • 206. Quintara Discovery
  • 207. Quotient Bioresearch
  • 208. ReadyCell
  • 209. Rebexsess Discovery Chemistry
  • 210. Red Glead Discovery
  • 211. Regulus Therapeutics
  • 212. ResearchPoint Global
  • 213. Rosa
  • 214. RTI International
  • 215. Sai Life Sciences
  • 216. Sandexis
  • 217. Sanofi
  • 218. Schrödinger
  • 219. Sekisui Medical
  • 220. Sekisui XenoTech
  • 221. Selcia
  • 222. Selvita
  • 223. Shanghai ChemPartner
  • 224. Shanghai Medicilon
  • 225. Shechter Computational Solutions
  • 226. Shire
  • 227. Sigma-Aldrich
  • 228. SilcsBio
  • 229. Simulations Plus
  • 230. SNBL USA
  • 231. SOLVO Biotechnology
  • 232. Spectris
  • 233. SPEware
  • 234. SRI International
  • 235. Strand Life Sciences
  • 236. Suven Life Sciences
  • 237. Sygnature Discovery
  • 238. Syngene
  • 239. Synovo
  • 240. Syntegrity Group
  • 241. TCG Lifesciences
  • 242. Tecan
  • 243. TestAmerica
  • 244. TetraQ
  • 245. The Carlyle Group
  • 246. The Institute for Transfusion Medicine
  • 247. The Michael J Fox Foundation
  • 248. Touchstone Biosciences
  • 249. TPG Capital
  • 250. Triskelion
  • 251. Unilabs
  • 252. University of California
  • 253. University of Pittsburgh
  • 254. Vanta Bioscience
  • 255. Villapharma Research
  • 256. Vipragen Biosciences
  • 257. Vitalant Research Institute
  • 258. Viva Biotech
  • 259. Vivo Bio Tech
  • 260. Vivotecnia
  • 261. WIL Research Laboratories
  • 262. Wildcard Pharmaceutical Consulting
  • 263. WuXi AppTec
  • 264. Xceleron
  • 265. XenoBiotic Laboratories
  • 266. Xenometrics
  • 267. XenoTech
  • 268. XtalPi
  • 269. Zumutor Biologics
Back to Top